Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast (APTA-2217) in Japanese Patients with COPD
NCT00242294Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Roflumilast with Placebo (2 arms). Primary endpoint: Change in lung function parameters (post-bronchodilator) at 24 weeks. Started Nov 2004; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00242294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242294.